Fate Therapeutics Director Departs; Filings Detail Compensation
Ticker: FATE · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-departure, compensation, filing
TL;DR
Fate Therapeutics director out, exec comp details filed. Board changes always worth watching.
AI Summary
On August 26, 2024, Fate Therapeutics, Inc. announced the departure of Dr. Wayne V. Saville from its Board of Directors. The company also reported on compensatory arrangements for certain officers and filed financial statements and exhibits. The filing does not specify the reasons for Dr. Saville's departure or details of the compensatory arrangements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director departures and details on executive compensation can sometimes indicate underlying issues or strategic shifts within a company.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- Dr. Wayne V. Saville (person) — Departing Director
- August 26, 2024 (date) — Date of earliest event reported
FAQ
What is the exact date of Dr. Wayne V. Saville's departure from the Board of Directors?
The filing indicates August 26, 2024, as the date of the earliest event reported, which includes the departure of directors.
Are the reasons for Dr. Saville's departure disclosed in this filing?
This 8-K filing does not specify the reasons for Dr. Wayne V. Saville's departure.
What other items are covered in this 8-K filing besides the director's departure?
The filing also covers compensatory arrangements of certain officers and the filing of financial statements and exhibits.
What is Fate Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 12278 Scripps Summit Dr., San Diego, CA 92131.
What is the SIC code for Fate Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Fate Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 787 words · 3 min read · ~3 pages · Grade level 14.3 · Accepted 2024-08-30 16:21:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share FATE The Nasdaq
Filing Documents
- d703760d8k.htm (8-K) — 28KB
- d703760dex101.htm (EX-10.1) — 76KB
- 0001193125-24-211130.txt ( ) — 245KB
- fate-20240826.xsd (EX-101.SCH) — 3KB
- fate-20240826_lab.xml (EX-101.LAB) — 17KB
- fate-20240826_pre.xml (EX-101.PRE) — 11KB
- d703760d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Amended and Restated Form of Indemnification Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 30, 2024 Fate Therapeutics, Inc. By: /s/ J. Scott Wolchko J. Scott Wolchko President and Chief Executive Officer